The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice

International Journal of Infectious Diseases

Volumn 10, Issue 5, 2006, Pages 401-406

  Luxameechanporn, Thongchai ^a   Blair, Christopher ^a   Kirtsreesakul, Virat ^a   Thompson, Kenneth ^a   Naclerio, Robert M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute sinusitis; Azithromycin; Mice; Moxifloxacin; Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; BACTERICIDE; CD11B ANTIGEN; CD3 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CELL MARKER; GALEX RELEASE1; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; EUTHANASIA; FEMALE; FLOW CYTOMETRY; INOCULATION; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; NOSE MUCUS; PATHOPHYSIOLOGY; POSTANTIBIOTIC EFFECT; RHINOSINUSITIS; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, CD11B; ANTIGENS, CD4; ANTIGENS, CD8; AZA COMPOUNDS; AZITHROMYCIN; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; QUINOLINES; RHINITIS; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 33746932162     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.07.007     Document Type: Article

References (30)

1. Benson V., and Marano M.A. Current estimates from the 1993 National Health Interview Survey. National Center for Health Statistics. Vital Health Stat 10 (1994) 190
2. McCaig L.F., and Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 273 (1995) 214-219
3. Luttinger A. The twisted life of DNA in the cell: bacterial topoisomerases. Mol Microbiol 15 (1995) 601-606
4. Bomer K., Brichta A., Baroody F., Boonlayangoor S., Li X., and Naclerio R.M. A mouse model of acute bacterial rhinosinusitis. Arch Otolaryngol Head Neck Surg 124 (1998) 1227-1232
5. Blair C., Nelson M., Thompson K., Boonlayangoor S., Haney L., Baroody F.M., et al. Allergic inflammation enhances bacterial sinusitis in mice. J Allergy Clin Immunol 108 (2001) 424-429
6. Wald E.R. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci 316 (1998) 13-20
7. Lister P.D., and Sander C.C. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43 (1999) 79-86
8. Morrissey I., and George J.T. Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method. Int J Antimicrob Agents 17 (2001) 33-37
9. Saravolatz L., Manzor O., Check C., Pawlak J., and Belian B. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 47 (2001) 875-877
10. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 43 Suppl B (1999) 51-59
11. Ostergaard C., Sorensen T.K., Knudsen J.D., and Frimodt-Moller N. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 42 (1998) 1706-1712
12. Saravolatz L.D., and Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 37 (2003) 1210-1215
13. Strahilevitz J., Lev A., Levi I., Fridman E., and Rubinstein E. Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. J Antimicrob Chemother 51 (2003) 665-669
14. Talan D.A. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32 (2001) S64-S71
15. Amin N.M., and Breadon G. An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Clin Ther 17 (1995) 701-707
16. den Hollander J.G., Knudsen J.D., Mouton J.W., Fuursted K., Frimodt-Moller N., Verbrugh H.A., et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 42 (1998) 377-382
17. Azoulay-Dupuis E., Vallee E., Bedos J.P., Muffat-Joly M., and Pocidalo J.J. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 35 (1991) 1024-1028
18. Girard A.E., Girard D., English A.R., Gootz T.D., Cimochowski C.R., Faiella J.A., et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 31 (1987) 1948-1954
19. Lacy M.K., Lu W., Xu X., Tessier P.R., Nicolau D.P., and Quintiliani R. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43 (1999) 672-677
20. Lister P.D., and Sanders C.C. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47 (2001) 811-818
21. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
22. Siefert H.M., Kohlsdorfer C., Steinke W., and Witt A. Pharmacokinetics of the 8-methoxyquinolones, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 43 (1999) B61-B67
23. Siefert H.M., Domdey-Bette A., Henninger K., Hucke F., Kohlsdorfer C., and Stass H.H. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 43 (1999) B69-B76
24. Otani T., Tanaka M., Ito E., Kurosaka Y., Murakami Y., Onodera K., et al. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother 47 (2003) 3750-3759
25. Miyazaki E., Miyazaki M., Chen J.M., Chaisson R.E., and Bishai W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43 (1999) 85-89
26. Gehanno P., Darantiere S., Dubreuil C., Chobaut J.C., Bobin S., Pages J.C., et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 49 (2002) 821-826
27. Zhanel G.G., and Noreddin A.M. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 1 (2001) 459-463
28. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
29. Bambeke F.V., and Tulkens P.M. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 18 (2001) S17-S23
30. Guggenbicher J., and Kastner U. Influence of antibiotics on the normal flora. Infect Med 15 Suppl (1998) 15-22